Search results
Results from the WOW.Com Content Network
Carcinoembryonic antigen (CEA) describes a set of highly-related glycoproteins involved in cell adhesion. CEA is normally produced in gastrointestinal tissue during fetal development, but the production stops before birth. Consequently, CEA is usually present at very low levels in the blood of healthy adults (about 2–4 ng/mL). [2]
In the literature, CEACAM5 is often used as a synonym for cancer embryonic antigen (CEA), a well-known biomarker of many types of malignancies, such as colorectal cancer and non-small-cell lung cancer. [4] [5] Its primary function in the embryonic intestine and colon tumors is adhesion between epithelial cells. [6]
Cancer biomarkers have also shown utility in monitoring how well a treatment is working over time. Much research is going into this particular area, since successful biomarkers have the potential of providing significant cost reduction in patient care, as the current image-based tests such as CT and MRI for monitoring tumor status are highly ...
Monitoring the malignancy; When a malignant tumor is found by the presence of a tumor marker, the level of marker found in the body can be monitored to determine the state of the tumor and how it responds to treatment. If the quantity stays the same during treatment it can indicate that the treatment isn't working, and an alternative treatment ...
Technetium (99m Tc) arcitumomab was a drug used for the diagnostic imaging of colorectal cancers, marketed by Immunomedics. [1]It consisted of the Fab' fragment of a monoclonal antibody (arcitumomab, trade name CEA-Scan) and a radionuclide, technetium-99m.
Over a 45-years span — between 1975 and 2020 — improvements in cancer screenings and prevention strategies have reduced deaths from five common cancers more than any advances in treatments ...
Labetuzumab (marketed under the trade name CEA-CIDE) is a humanized IgG1 monoclonal antibody for the treatment of colorectal cancer. [1] It selectively binds to carcinoembryonic cell adhesion molecule 5. [2] Also tried in patients with MTC (medullary thyroid carcinoma) with metastasis. This drug was developed by Immunomedics, Inc.
Tumor-associated glycoprotein 72 (TAG-72) is a glycoprotein found on the surface of many cancer cells, including ovary, [1] [2] [3] breast, colon, [4] lung, and pancreatic cancers.